36 results about "Metabolic effects" patented technology

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca<2+>-channels or on the [<3>H]-ryanodine receptors of the retinal pigment epithelium.

A method of obtaining beneficial biological results associated with caloric restriction may be gained by administration of a composition containing at least one active agent which blocks metabolism of glucose as a source of energy in cells in glucose metabolism blocking effective amounts to an animal in need thereof.

The present invention is based, in part, upon the discovery that the use of an anti-HIV drug in combination with at least one cortisol blocker such as procaine, reduces the side effects associated with anti-HIV drugs. The invention also relates to a method of treating the high cortisol catabolic effects of diseases such as AIDS in the HIV positive population and those with AIDS related complexes by the administration of a cortisol blocker. The present invention also discloses a composition comprising an anti-HIV drug and cortisol blocker. More specifically, the present invention relates to a cortisol blocking composition which comprises procaine, ascorbic acid and zinc heptahydrate.

A topical medicament for use in treating tissues comprising: an enhancer for facilitating non-invasive, transdermal delivery and / or enhancing metabolic effect of a therapeutic dosage of LEVULAN® KERASTICK™ (aminolevulinic acid HCl) into a tissue. The present invention provides a topical, transdermal medicament for use in treating tissues comprising an enhancer for facilitating non-invasive, transdermal delivery of a therapeutic dosage of comprising LEVULAN® KERASTICK™ (aminolevulinic acid HCl) into a tissue for example wherein the enhancing agent is comprising L.M.X.4®The enhancer may be selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water or combinations thereof. The present invention, also, provides a pharmaceutical composition useful for treating tissues in humans and animals which comprises a therapeutically effective amount of LEVULAN® KERASTICK™ (aminolevulinic acid HCl) or pharmaceutically acceptable salt thereof in combination with a synergistically effective amount of at least one enhancer or pharmaceutically acceptable carrier wherein said enhancer is selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water. The invention, also, provides a method of treating or preventing a human or animal afflicted by a diseases comprising topically administering a pharmaceutical composition which comprises of a therapeutically effective amount of aminolevulinic acid HCl in combination with an enhancer and / or a pharmaceutically acceptable carrier. The invention, also, provides a method wherein the composition further comprises a synergistically effective amount of an enhancer and / or pharmaceutically acceptable salt thereof wherein said enhancer is selected from the group consisting of lidocaine, benzyl, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate, water and combinations thereof.

L-cells may be introduced in the gastrointestinal tract. L-cells are used in the digestive process to produce a more efficient and lasting means of regulating feelings of satiation in a patient. Desired metabolic effects may be achieved by manipulating L-cells via delivery sites, frequency of delivery, or type of biological substance delivered.

A novel omega-3 fatty acid / lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid / lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPARα receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.

A laser irradiation system, method, and apparatus that can generate optical energy at a specific or a range of wavelengths, power levels, and beam profiles, among others, to treat acute or chronic inflammation, wounds, and autoimmune deficiency conditions without ablating the target tissue or surrounding tissue. In one aspect, the light beam of the laser irradiation system, method, and apparatus can stimulate photoreceptors within a cell, thereby initiating a cascade of secondary cellular metabolic effects and normalizing cellular activity towards homeostasis, among other advantages.

The invention relates to a fermentation product prepared by Chinese medicinal materials and Auricularia Polytricha(Mont)Sacl, a preparation method thereof, a derivative product of the fermentation product, and application thereof in the fields of medicine and health-care food. The invention solves the technical problems by providing a novel fermentation product with functions of activating blood and dissolving stasis, resisting inflammation and reliving pain, preventing lipid peroxidation, removing free radicals, enhancing immunity and promoting metabolism. Taking the Auricularia Polytricha(Mont)Sacl as an initial mycelium, by adding radix salviae miltiorrhizae into a culture medium, a thalli mixture containing the mycelium and the culture medium is obtained by adopting a solid fermentation mode. Proved by related pharmacological tests, compared with the radix salviae miltiorrhizae, the solid fermentation product has the efficacies equal to or higher than the radix salviae miltiorrhizae in the aspect of the functions of activating blood and dissolving stasis, resisting inflammation and reliving pain, preventing lipid peroxidation, removing free radicals, enhancing immunity and promoting metabolism.

The invention is concerned with a method and a composition for treating or preventing catabolism or of stimulating anabolism in a mammal undergoing metabolic stress. The method comprises administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least 0.18 mmol per kg of body weight per day.

The invention discloses an ecological agriculture planting greenhouse which structurally comprises a ceiling multifunctional frame, a ventilation pipe, a greenhouse body, an access door and a protection enclosure. A left shield and a right shield are enabled to rotate around axis of deflection by a certain angle, sunlight is enabled to enter through a gap opened by the left shield and the right shield, time of sunlight radiation received by different crops in each day can be adjusted subtly, and metabolic effect of the crops is better; after the left shield and the right shield are opened whenthe crops need the sunlight, an adjusting button can be rotated to enable a water glass plate to rotate onto a horizontal plane according to illumination intensity needed by different crops, the water glass plates in different amounts are opened according to different crops, and the water glass plates can refract and weaken illumination intensity to reduce the intensity so as to enable the illumination intensity received by the crops to be optimal.

The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the peroxisome proliferator-activated receptors (PPAR) and which, therefore, modulate the actions regulated by said receptors, such as inducing satiety, controlling ingestion and modulating metabolic effects, and thus are useful for the administration thereof as a pharmacological tool and as drugs for the treatment and / or prevention of metabolic diseases and cardiovascular diseases.

The present invention relates to a use of composition comprising a glucose anti-metabolite and / or source of glucose anti-metabolite in a method of enhancing a positive affect and / or energetic arousal in a mammal.

The invention belongs to the technical field of western medicine preparation, and specifically provides a CYP17 inhibitor soft capsule. The abiraterone acetate is dissolved in fatty glyceride to makea uniform clear solution, and the soft capsule is filled with the solution. The use of fatty glyceride in the soft capsule can stimulate the contraction of bile vesicles, increases the concentration of bile salts, phospholipids and cholesterol in the small intestine, and improves the dissolution and solubility in the body, prolongs the gastrointestinal retention time, stimulates lymphatic transport, reduces metabolic effects, and further increases the bioavailability of abiraterone acetate.

The invention relates to a drug for treating rectal cancer and gastric cancer, which is composed of the following components according to the weight percentage: 0.5 to 5 percent of malt juice, 0.5 to 4 percent of peptone, 1 to 6 percent of glucose, 1 to 6 percent of alcohol, 1 to 20 percent of crystal sugar, 1.5 to 17 percent of acetic acid bacteria, 1.5 to 17 percent of yeast and 1.5 to 17 percent of Beta-glucan. The drug is a collection of multiple non-parasitic bacteria and B-vitamin organic matters. The drug cleverly carries out the metabolism by the biological symbiotic state via a symbiosis state of micro-organisms and simultaneously dissolves the products generated by the metabolism for forming multiple effects. The drug is vital, which can grow but can not move, thus directly benefiting human body.

The invention discloses an acidic carboxymethylcellulose condensate treatment method. The acidic CMC condensate firstly enters an adjusting sedimentation tank to adjust the water amount and water quality, and then enters a neutralizing tank. A Na2CO3 solution is added into the neutralizing tank to allow the pH value of waste water to be stabilized between 6.5 to 7.5. The waste water is purified through a UBF reactor in an anaerobic manner and flows into a BAF reactor, and is purified through an aerobic biofilm to discharge or reuse. The UBF reactor is filled with polyurethane-based porous rotating spherical filler and the BAF reactor is filled with clinoptilolites and bio-ceramics as fillers, and the UBF reactor and the BAF reactor respectively culture and acclimate anaerobic biofilms and aerobic biofilms, metabolic effects, filtration effects and multi-stage biological predator effects of heterotrophic bacteria on the biofilms are utilized, and biological purification of the CMC condensate is realized.

A novel omega-3 fatty acid / lipid based nutritional composition and a method of optimizing said omega-3 fatty acid / lipid based nutritional composition. The nutritional compositions and methods are based on the insight that different forms of high omega-3 fatty acid lipids (eg, triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically, the phospholipid form may be more effective in promoting membrane fluidity and permeability, while the free fatty acid form may be more effective in modulating cellular receptors, such as PPARa receptors, which are responsible for different metabolic actions, including fat metabolisim. Favorable conditions for producing omega-3 compositions that can act synergistically and thus more robustly improve health and to some extent mimic markers of life extension such as shown by caloric restriction are taught along with specific optimization methods , markers, and compositions.